NeoGenomics to Present New Research at ASCO Annual Meeting 2026

NeoGenomics, Inc., the leading provider of oncology diagnostic solutions that enable precision medicine, has announced the showcase of eight scientific abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting.
This helps to demonstrate NeoGenomics' expanding capabilities across the company’s clinical oncology testing and data solutions, spanning hematologic malignancies, solid-tumor genomic profiling, the real-world impact of insurance coverage gaps on next-generation sequencing (NGS) testing, and the detection of circulating tumor DNA (ctDNA) through molecular residual disease (MRD).

According to Towards Healthcare, the U.S. non-invasive cancer diagnostics market is projected to experience significant growth, with estimates suggesting the market size will increase from USD 42.58 billion in 2026 to approximately USD 107.53 billion by 2035, representing a compound annual growth rate (CAGR) of 10.84% from 2026 to 2035. Growth is driven by a shift toward an aging populace, which inherently increases cancer prevalence, fueling the need for routine, less-taxing screening alternatives and increased use of genetic profiling and AI-driven diagnostics for targeted therapies, which require less-invasive tissue collection methods. 

About NeoGenomics

NeoGenomics will also debut its updated mission, partnering with physicians to deliver actionable insights that guide personalized treatment decisions and improve outcomes, and a new vision of a world where every cancer treatment decision is as personal as the patient.

The company is also developing a low-sample-input acute myeloid leukemia (AML) MRD flow assay designed to deliver higher sensitivity and faster turnaround times compared to currently available assays. This approach may enable more confident relapse risk prediction, therapeutic response assessment, and MRD endpoint tracking in hematologic trials, even when sample availability is limited.

CEO of NeoGenomics, Tony Zook, stated the cancer diagnosis is the beginning of a long road, and NeoGenomics is committed to being there from the first diagnosis through recurrence monitoring.

A recent report by Towards Healthcare highlights that the U.S. non-invasive cancer diagnostics market is witnessing growth driven by the rising cancer prevalence & aging population, the U.S. demographic aging, and cancer rates increasing, and there is a mounting need for minimally invasive, accessible screening to manage the disease burden. The integration of artificial intelligence and digital pathology enables automated, high-accuracy image interpretation. This opportunity helps address radiologist shortages while accelerating personalized oncology treatments.